ATAI250117C1500
- 0.17
- 0.000.00%
ATAI Life Sciences Newsroom
Psychedelic Drug Developer Lykos Could Get Lifeline From Former Tesla Board Member
Atai Life Sciences Appoints Gerd Kochendoerfer As COO; Srinivas Rao Assumes Sole CEO Role
ATAI Life Sciences Revamps Leadership Amid Clinical Trials
ATAI Life Sciences: Kevin Craig Named Chief Medical Officer >ATAI
Atai Life Sciences Names Srinivas Rao as Sole CEO
Press Release: Atai Life Sciences Announces Key Leadership Appointments as It Advances Its Pipeline of Novel Psychedelic Therapeutics for Mental Health
HC Wainwright & Co. Maintains Buy on ATAI Life Sciences, Lowers Price Target to $10
ATAI Life Sciences Price Target Maintained With a $11.00/Share by Canaccord Genuity
ATAI Life Sciences Analyst Ratings
Maxim Group Maintains ATAI Life Sciences(ATAI.US) With Buy Rating, Maintains Target Price $6
Express News | U.S.-Listed Shares of ATAI Life Sciences up 9.1%
RFK and the 'MAHA Trade': Vaccine Makers Down, Psychedelic Shares up
ATAI Life Sciences | 10-Q/A: Quarterly report (Amendment)
Atai Life Sciences Advances Psychedelic Treatments in Q3 2024
TD Cowen Maintains ATAI Life Sciences(ATAI.US) With Buy Rating
TD Cowen Sticks to Its Buy Rating for ATAI Life Sciences (ATAI)
ATAI Life Sciences | 10-Q: Q3 2024 Earnings Report
AI And Psychedelics: A Marriage Made In Heaven For Mental Health Care?
Atai Q3 Report: Strong Cash Position, Clinical Pipeline Growth
Atai Life Sciences Advances Therapeutic Pipeline in Q3 With FDA Approval of VLS-01 | NASDAQ:ATAI, ETR:9VC